BioCentury
ARTICLE | Clinical News

Takeda reports Phase III data for diabetes compound

May 17, 2013 1:32 AM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said once-daily 25 and 50 mg oral fasiglifam each met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo in the Phase III CCT-003 t...